Neurocrine Biosciences, Inc. (NBIX) Balance Sheet

The shift from accumulated deficit territory to a retained earnings balance above $800M indicates sustained profitability over the period. Equity growth from $2.5B to $3.9B outpaced liability growth, which may signal improving financial resilience. Investors should monitor whether this pace is sustainable given the quarterly volatility visible in earnings.

The 2025Q3 debt spike appears to be a temporary financing event rather than a structural leverage trend, given the rapid reversal. Current debt of roughly $392M is modest relative to $5.6B in total assets, suggesting limited refinancing pressure. The data does not disclose debt maturity schedules, so refinancing risk cannot be fully assessed.

A current ratio above 2.0 indicates the company holds comfortable short-term coverage, though the decline from the 2024 peak reflects growing current liabilities. Cash of $641.5M provides a meaningful buffer against operating shocks. Liquidity appears adequate, but the data alone does not reveal near-term cash burn commitments.

The sharp increase in goodwill from negligible levels suggests a material acquisition closed during 2025Q4 to 2026Q1, shifting the asset mix toward intangibles. Goodwill carries impairment risk if acquired economics underperform, which would hit equity directly given the company's current retained earnings base. Property, plant and equipment of $529.4M remains a smaller share, indicating a relatively asset-light model.